【限時領取專業報告】雙特異性抗體(BSAB)開發和製造之加速策略

Bispecific Antibody (BsAb) Development and Manufacture

In this e-book, Lonza experts review important aspects of developing and manufacturing bispecific antibodies (bsAbs), with editorial highlights from the past year. Read on to discover the impact that poor assembly and expression can have on downstream purification and formulation, and how addressing these challenges at an early stage, using specialized strategies and technologies, ensures cost-effective production of high quality bsAb-based drug candidates to tight timelines.

Authors:
Alice Harrison, DPhil, Global Technical CMC and CMC Director, Analytics
Lisa Prendergast, PhD, Associate Director, Expression System Sciences in Licensing
Rebecca Michael, PhD, Principal Group Leader, Cell and Molecular Biology Group
Karl Rogerson, MSc, Senior Principal Scientist, Global Process and Analytical Development Sciences
Stuart Jamieson, PhD, Global Technical and CMC Director, Downstream Development
Andrew Brown, EngD, PhD, Support Manager, Global Process Development

點此領取 
-4月限時領取!!
-於網站填寫姓名、公司等基本資料後即可下載
 

 
Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We focus on enabling treatments that prevent illness and support healthier lifestyles. We optimize scientific innovation and manufacturing technology to enable our customers to serve their patients and consumers.

We provide a wide range of services and products from early phase discovery to custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries. Our scale and resources mean we can provide a one-stop solution for our customers to help people get well, feel well, and stay well. In 2021, we supported more than 780 preclinical and clinical small and large molecules, more than 245 commercial small and large molecules and produced around 250 billion capsules.